Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$1.62
+3.5%
$2.38
$1.46
$316.92
$2.41M0.4492,378 shs20,676 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.08
-0.1%
$0.10
$0.08
$0.47
$860K0.457,573 shs741 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.15
-7.4%
$0.13
$0.06
$6.80
$3.16M0.46588,923 shs19,777 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$2.31
-1.1%
$2.92
$2.10
$17.49
$3.28M-0.03382,474 shs11,449 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-7.69%-17.02%-19.59%-63.55%-99.22%
Dynatronics Co. stock logo
DYNT
Dynatronics
-0.12%-0.12%-19.00%-27.09%-79.39%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.00%+7.78%+47.27%+29.60%-96.82%
Venus Concept Inc. stock logo
VERO
Venus Concept
+1.75%+4.95%-4.12%-30.64%-60.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
1.132 of 5 stars
0.05.00.00.03.00.00.6
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
0.8143 of 5 stars
0.03.00.00.01.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$5.003,233.33% Upside
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$250K9.65N/AN/A$934.50 per share0.00
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.03N/AN/A$0.57 per share0.14
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.41N/AN/A($6.91) per share-0.02
Venus Concept Inc. stock logo
VERO
Venus Concept
$61.00M0.05N/AN/A($2.43) per share-0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$9.95M-$379.74N/AN/AN/A-155.67%-117.82%N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.78N/AN/A-8.35%-41.81%-9.56%N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%5/30/2025 (Estimated)
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$76.30N/AN/A-74.62%N/A-47.46%8/11/2025 (Estimated)

Latest DYNT, TTOO, VERO, and BJDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Venus Concept Inc. stock logo
VERO
Venus Concept
-$14.08-$17.44-$3.36-$17.44$14.59 million$13.64 million
5/13/2025Q1 2025
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A-$3.37N/A-$3.37N/AN/A
3/31/2025Q4 2024
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$36.00-$112.37-$76.37-$112.37N/AN/A
3/31/2025Q4 2024
Venus Concept Inc. stock logo
VERO
Venus Concept
-$10.0089-$11.23-$1.2211-$11.23$16.99 million$15.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
6.26
6.26
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24
Venus Concept Inc. stock logo
VERO
Venus Concept
2.83
1.86
1.18

Institutional Ownership

CompanyInstitutional Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
0.37%
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
Venus Concept Inc. stock logo
VERO
Venus Concept
28.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
91.49 million551,000Not Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20010.62 million8.11 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable
Venus Concept Inc. stock logo
VERO
Venus Concept
4101.42 million3.70 millionNot Optionable

Recent News About These Companies

Venus Concept announces $11M debt-to-equity exchange transaction
Venus Concept reports Q4 EPS ($11.23) vs ($20.14) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bluejay Diagnostics stock logo

Bluejay Diagnostics NASDAQ:BJDX

$1.62 +0.06 (+3.53%)
As of 12:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.08 0.00 (-0.12%)
As of 10:33 AM Eastern

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.15 -0.01 (-7.41%)
As of 11:43 AM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Venus Concept stock logo

Venus Concept NASDAQ:VERO

$2.31 -0.03 (-1.07%)
As of 12:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.